Cannabis Safety for Adults Over 50: What Polypharmacy and Age-Related Physiology Change About the Risk

No — two things have changed substantially. First, cannabis potency has increased dramatically. Average THC content in products available in the 1970s was estimated at 1–2%. Legal market dispensary products today routinely reach 20–30% THC, and concentrates exceed that. Edibles have precise but sometimes high THC doses. Previous use history at historical potency levels does not predict response to current product potency.

Second, your medication context has almost certainly changed. At 65, the probability that you are on statins, blood pressure medications, anticoagulants, or other prescriptions with cannabis interaction potential is substantially higher than it was in your 20s or 30s. The cannabis is potentially similar in nature — the pharmacological environment you are taking it into is not.

Yes. Many prescribers do not routinely ask about cannabis — either because of clinical workflow habits or uncertainty about how to counsel on it. This does not mean they do not want to know, or that it is not clinically relevant. A prescriber cannot appropriately monitor your warfarin INR, your statin side effects, or your blood pressure control without knowing that you use cannabis, because cannabis can affect all of these through documented mechanisms.

A straightforward way to raise it: "I want to make sure you know I occasionally use cannabis products — I wanted to flag it in case it's relevant to any of my medications." Most prescribers will respond positively to this level of proactive disclosure. Use the InteractSafe checker to review your specific medications before the appointment so you can bring a concrete starting point to the conversation.

Not straightforwardly, no. CBD oil — particularly high-concentration CBD oil used daily — is actually the higher pharmacokinetic interaction risk option for the CYP enzyme pathway. CBD is a more potent CYP2C9, CYP2D6, and CYP3A4 inhibitor than THC. High-CBD products taken orally create sustained liver enzyme inhibition that raises blood levels of co-administered medications in the ways described throughout this site.

THC-dominant products (smoked flower with low CBD) carry less pharmacokinetic interaction but have their own cardiovascular and CNS pharmacodynamic concerns. Neither is categorically "safer" for someone on multiple medications — they carry different interaction profiles. The relevant question is which specific medications are involved and what a prescriber-reviewed assessment says about the individual combination.

Some older adults use cannabis specifically for pain management, and some evidence suggests cannabinoids have analgesic properties for certain pain types. The practical interaction risk for this use case depends on the specific medications involved. For pain management, topical CBD products (applied to skin) carry the lowest systemic interaction risk because they produce minimal systemic absorption. Oral or inhaled cannabis for pain in someone on multiple medications carries the interaction concerns detailed throughout this site. Evidence-based non-cannabis pain options with better established safety profiles for older adults should be reviewed with the prescriber before pursuing cannabis for pain management. This conversation is particularly important because some cannabis products marketed for pain contain variable amounts of THC and CBD that can be difficult to quantify accurately.